Successful liver transplantation in short telomere syndromes without bone marrow failure due to DKC1 mutation

2020 ◽  
Vol 24 (3) ◽  
Author(s):  
Rodrigo del Brío Castillo ◽  
Jacob Bleesing ◽  
Thomas McCormick ◽  
James E. Squires ◽  
George V. Mazariegos ◽  
...  
2017 ◽  
Author(s):  
Jonathan K. Alder ◽  
Vidya Sagar Hanumanthu ◽  
Margaret A. Strong ◽  
Amy E. DeZern ◽  
Susan E. Stanley ◽  
...  

AbstractVery short telomere length (TL) provokes cellular senescence in vitro, but the clinical utility of TL measurement in a hospital-based setting has not been determined. We tested the diagnostic and prognostic value of TL measurement by flow cytometry and fluorescence in situ hybridization (flowFISH) in individuals with mutations in telomerase and telomere maintenance genes, and examined prospectively whether TL altered treatment decisions for patients with bone marrow failure. TL had a definable normal range across populations with discrete lower and upper boundaries. TL above the 50th age-adjusted percentile had a 100% negative predictive value for clinically relevant mutations in telomere maintenance genes, but the lower threshold for diagnosis was age-dependent. The extent of deviation from the age-adjusted median correlated with the age at diagnosis of a telomere syndrome as well as the predominant complication. Mild short telomere defects manifested in adults as pulmonary fibrosis-emphysema, while severely short TL manifested in children as bone marrow failure and immunodeficiency. Among 38 newly diagnosed patients with bone marrow failure, TL shorter than the 1st age-adjusted percentile enriched for patients with germline mutations in inherited bone marrow failure genes, such as RUNX1, in addition to telomere maintenance genes. The TL result modified the hematopoietic stem cell donor choice and/or treatment regimen in one-fourth of the cases (9 of 38,24%). TL testing by flowFISH has diagnostic and predictive value in definable clinical settings. In patients with bone marrow failure, it altered treatment decisions for a significant subset.


Hematology ◽  
2021 ◽  
Vol 2021 (1) ◽  
pp. 134-142
Author(s):  
Siobán Keel ◽  
Amy Geddis

Abstract The overlap in clinical presentation and bone marrow features of acquired and inherited causes of hypocellular marrow failure poses a significant diagnostic challenge in real case scenarios, particularly in nonsevere disease. The distinction between acquired aplastic anemia (aAA), hypocellular myelodysplastic syndrome (MDS), and inherited bone marrow failure syndromes presenting with marrow hypocellularity is critical to inform appropriate care. Here, we review the workup of hypocellular marrow failure in adolescents through adults. Given the limitations of relying on clinical stigmata or family history to identify patients with inherited etiologies, we outline a diagnostic approach incorporating comprehensive genetic testing in patients with hypocellular marrow failure that does not require immediate therapy and thus allows time to complete the evaluation. We also review the clinical utility of marrow array to detect acquired 6p copy number-neutral loss of heterozygosity to support a diagnosis of aAA, the complexities of telomere length testing in patients with aAA, short telomere syndromes, and other inherited bone marrow failure syndromes, as well as the limitations of somatic mutation testing for mutations in myeloid malignancy genes for discriminating between the various diagnostic possibilities.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1036-1036
Author(s):  
Jun Lu ◽  
Susan Wong ◽  
Atanu Basu ◽  
Neal S. Young ◽  
Kevin E. Brown

Abstract In hepatitis-associated aplastic anemia (HAA), bone marrow failure follows an acute attack of seronegative hepatitis. Aplastic anemia (AA) is also associated with orthotopic liver transplantation for non-A, non-B, non-C hepatitis in young patients. Although the etiology of HAA is unknown, a clinical response to immunosuppressive therapy is observed in most clinical cases. The liver is the potential initial target organ of the immune response. We have previously determined the T-cell repertoire in the liver and peripheral blood lymphocytes in patients with HAA (Lu et al. Blood. 2004 Jun 15;103(12):4588–93). An antigen-driven T-cell expansion was implicated in the acute stage before bone marrow failure. In the present study, we measured serum cytokine levels in 22 HAA serum samples. Only interleukin (IL)-10 levels showed a significant increase compared to healthy controls (p<0.02); IFN-γ , TNF-α and IL-1, 2, 4, 5, 6, 8, 12 levels showed no significant difference. To further characterize the immune response in the liver, we performed RNAse protection assays and realtime PCR for RNA transcripts. In 4 HAA liver samples, 2 demonstrated increased IFN-γ by RNAse protection; TNF-α , IL-2, 3, 4, 5, 10, 15 transcripts were not different compared to transcript levels in 4 hepatitis B and/or C livers and 2 fulminant hepatitis (FH) samples. To confirm our preliminary data, we characterized the cytokine profile including CD4, CD8, CD69, TNF-α , IFN-γ and interleukins and compared them among the hepatitis B/C, FH and HAA liver samples by quantitative PCR for RNA transcripts. In 10 HAA liver samples, CD8 transcripts were increased and the CD4/CD8 ratio was decreased, but there was no significant difference between HAA and hepatitis B/C (p>0.05), confirming the important role of cellular immunity in HAA. IFN-γ transcripts were significantly overexpressed in both HAA and FH samples compared to hepatitis B/C samples (p<0.05), but without a difference between HAA and FH. CD69 transcripts were reduced in HAA but not significantly lower than in hepatitis B/C (p<0.05). There were no difference of TNF-α transcripts among HAA, hepatitis and FH samples (p>0.05). In summary, our data confirm that enhanced cellular immunity (increased IFN-γ level) is implicated in the pathogenesis of HAA, similar to that observed in the bone marrow of idiopathic AA, and in contrast to other liver diseases such as chronic hepatitis B/C. Quantitation of IFN-γ levels in acute hepatitis samples might be a predictive marker for the development of bone marrow failure after liver transplantation following seronegative hepatitis and FH.


Sign in / Sign up

Export Citation Format

Share Document